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Markers of Angiogenesis Associated with Surgical Attenuation of
Congenital Portosystemic Shunts in Dogs
M.S. Tivers, A.K. House, K.C. Smith, C.P.D. Wheeler-Jones, and V.J. Lipscomb
Background: Dogs with congenital portosystemic shunts (CPSS) have hypoplasia of the intrahepatic portal veins. Surgi-
cal CPSS attenuation results in the development of the intrahepatic portal vasculature, the precise mechanism for which is
unknown, although new vessel formation by angiogenesis is suspected.
Hypothesis: That the degree of portal vascular development and the increase in portal vascularization after CPSS atten-
uation is significantly associated with hepatic vascular endothelial growth factor (VEGF) and VEGF receptor 2 (VEGFR2)
gene expression and serum VEGF concentration.
Animals: Client-owned dogs with CPSS undergoing surgical treatment. Forty-nine dogs were included in the gene
expression data and 35 in the serum VEGF data.
Materials and Methods: Dogs surgically treated by partial or complete CPSS attenuation were prospectively recruited.
Relative gene expression of VEGF and VEGFR2 was measured in liver biopsy samples taken at initial and follow-up sur-
gery using quantitative polymerase chain reaction. Serum VEGF concentration was measured before and after CPSS atten-
uation using a canine specific ELISA. Statistical significance was set at the 5% level (P ≤ .05).
Results: There was a significant increase in the mRNA expression of VEGFR2 after partial attenuation (P = .006).
Dogs that could tolerate complete attenuation had significantly greater VEGFR2 mRNA expression than those that only
tolerated partial attenuation (P = .037). Serum VEGF concentration was significantly increased at 24 (P < .001) and 48
(P = .003) hours after attenuation.
Conclusions and Clinical Importance: These findings suggest that intrahepatic angiogenesis is likely to occur after the
surgical attenuation of CPSS in dogs, and contributes to the development of the intrahepatic vasculature postoperatively.
Key words: Canine; Liver; Quantitative polymerase chain reaction; Vascular endothelial growth factor.
Dogs with congenital portosystemic shunts (CPSS)have decreased portal blood supply and hence an
underdeveloped intrahepatic portal vasculature as
assessed by portovenography.1 Surgical attenuation of
the CPSS is recommended to redirect portal blood
flow and restore normal hepatic function.2 CPSS
attenuation results in a substantial increase in the
intrahepatic portal vasculature, as assessed by portove-
nography, and is associated with improvement in
clinical signs.1 The growth and maturation of new ves-
sels is a highly complicated process and vascular
endothelial growth factor (VEGF) is a critical media-
tor of angiogenesis.3 VEGF promotes angiogenesis
predominantly through VEGF receptor 2 (VEGFR2).3
There is an increase in liver volume after CPSS
attenuation4,5 and it is probable that this increase is
associated with the formation of new blood vessels to
support the new liver tissue. We have previously
demonstrated that improvement in the portal vascula-
ture is associated with decreased VEGF protein expres-
sion and increased VEGFR2 protein expression in liver
tissue, suggesting that angiogenesis is involved.6 How-
ever, it was recognized that additional work was required
to investigate the precise role of angiogenesis in the hepa-
tic vascular response to CPSS attenuation. A better
understanding of this process may allow more accurate
prognostication and the development of novel therapies.
The overall aim of this study was to determine
whether markers of angiogenesis are associated with the
vascular response to CPSS attenuation. The study had 2
specific aims. The first was to measure the mRNA
expression of VEGF and VEGFR2 in liver biopsy sam-
ples from dogs with CPSS both initially and after partial
CPSS attenuation. The second aim was to measure the
serum concentrations of VEGF in dogs with CPSS
before and after attenuation.
The hypotheses tested were that gene expression
would be significantly associated with the degree of por-
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tal vascular development, would significantly change in
response to surgical CPSS attenuation, and that surgical
CPSS attenuation would result in acute changes in
serum VEGF concentration.
Materials and Methods
Clinical Management
Dogs with CPSS were prospectively recruited between August
2007 and October 2011. An institutional Ethics Committee
granted ethical approval and owners gave full informed consent.
Dogs were treated surgically by suture attenuation of their
CPSS.1 Dogs that could not tolerate complete attenuation,
because of portal hypertension, were treated with partial attenua-
tion. Dogs treated with partial attenuation had repeat surgery
approximately 3 months postoperatively to attempt complete
attenuation. Portovenography was performed before and after
temporary complete shunt attenuation at each surgery to assess
the development of the intrahepatic portal vasculature.1 Portove-
nography grade was determined according to the number of gen-
erations of intrahepatic portal vessels that were visible on a scale
of 1–4.1 Portovenogram grades of 1 and 2 represented poor por-
tal blood flow and portovenogram grades of 3 and 4 represented
good portal blood flow.
Healthy experimental Beagle dogs, which had been humanely
destroyed for reasons unrelated to hepatic disease, were used as
controls for gene expression and serum VEGF measurement. In
addition, dogs undergoing exploratory laparotomy were included
as controls for serum VEGF measurement.
qPCR Gene Expression
For CPSS dogs, at each surgery a liver biopsy was taken for
routine diagnostic purposes and a portion was placed in an
appropriate volume of RNAlater,a placed at 4°C for 24 hours
and then frozen at 80°C. Liver tissue was taken from Beagle
control dogs immediately after euthanasia and was processed and
stored as described above.
RNA was extracted from approximately 20–30 mg of each
hepatic sample using the GenElute Mammalian Total RNA
Miniprep Kit.a The tissue was homogenized in 500 lL Lysis
Solution using a Mixer Mill MM 300.b An in-solution DNase
digestion was performed using the Ambion TURBO DNA-free
Kitc to remove any contaminating DNA. RNA quality and
quantity was assessed by microfluidic capillary electrophoresis
using the Agilent 2100 Bioanalyser.d Two separate cDNA were
synthesized from each RNA sample using a mixture of random
hexamer and oligo (dT)15 primers
e and IMProm-II reverse trans-
criptase enzyme.e Where possible, the amount of RNA template
for cDNA synthesis was standardized at 1 lg. The cDNA was
diluted to a final volume of 100 lL with nuclease-free water and
stored at 20°C before further use.
Quantitative polymerase chain reaction was used to measure
the relative hepatic expression of VEGF and VEGFR2. Previ-
ously published canine gene specific primers for the genes of
interest7 and 4 liver-specific reference genes8: hydroxymethyl-
bilane synthase (HMBS), ribosomal protein L13a (RPL13A),
ribosomal protein L32 (RPL32), and ribosomal protein S18
(RPS18) were used (Table 1).
For quantification, each liver sample had 2 cDNA samples
analyzed in duplicate. Reactions were carried out in 25 lL vol-
umes using a Bio-Rad CFX96 Real-Time PCR Detection System
thermocycler.f Each reaction consisted of 1 lL cDNA as the tem-
plate with Immobufferg (19 concentration), Hi-Spec Additiveg
(19 concentration), dNTPg (final concentration 1 mM), magne-
sium chloride (final concentration 2.5 mM for genes of interest,
4.5 mM for reference genes), 1 unit Immolase DNA polymeraseg
and EvaGreen dyeh (0.069 diluted 1:4 with nuclease-free water).
Samples were incubated at 95°C for 10 minutes followed by 40
cycles of denaturation at 94°C for 30 seconds, annealing at 55°C
for 30 seconds and elongation at 72°C for 10 seconds. An appro-
priate primer-dimer melting temperature for 1 second was pro-
grammed before fluorescence readings were taken at the end of
each cycle. A melting curve analysis from 65°C to 95°C with a
plate read every 0.5°C was performed at the end of 40 cycles.
Bio-Rad CFX Manager Softwaref was used for initial qPCR
analysis.
Analysis of raw real-time data was performed using GenEx
professional version 4.4.2 software.i Relative gene expression was
quantified as previously described.9 Quantification cycle (Cq) val-
ues were corrected using the calculated efficiencies for each pri-
mer set. Normalization of each sample Cq for the genes of
interest was performed relative to the geometric normalization
of the 4 reference genes. The relative expression of the genes of
interest in each cDNA sample was calculated using the normal-
ized Cq of each sample relative to the average Cq of all of the
samples.
Table 1. Table showing details of reference gene and gene of interest primer pairs for qPCR.
Gene Primer Sequences
PCR Amplicon
Length (bp)
Genbank Accession
Number
Primer Sequence
Reference
HMBS Forward: TCACCATCGGAGCCATCT
Reverse: GTTCCCACCACGCTCTTCT
112 XM546491 Peters et al8
RPL13A Forward: GCCGGAAGGTTGTAGTCGT
Reverse: GGAGGAAGGCCAGGTAATTC
87 AJ388525 Peters et al8
RPL32 Forward: TGGTTACAGGAGCAACAAGAAA
Reverse: GCACATCAGCAGCACTTCA
100 XM_848016 Peters et al8
RPS18 Forward: TGCTCATGTGGTATTGAGGAA
Reverse: TCTTATACTGGCGTGGATTCTG
116 XM_532106 Peters et al8
VEGF Forward: CTTTCTGCTCTCCTGGGTGC
Reverse: GGTTTGTGCTCTCCTCCTGC
101 NM_001003175 Kummeling et al7
VEGFR2 Forward: GGAAGAGGAAGTGTGTGACCCC
Reverse: GACCATACCACTGTCCGTCTGG
181 XM_539273 Kummeling et al7
qPCR, quantitative polymerase chain reaction; HMBS, hydroxymethyl-bilane synthase; RPL13A, ribosomal protein L13a; RPL32,
ribosomal protein L32; RPS18, ribosomal protein S18; VEGF, vascular endothelial growth factor; VEGFR2, vascular endothelial
growth factor receptor 2.
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Serum VEGF Concentration
Blood samples were taken from CPSS dogs and exploratory
laparotomy controls preoperatively for diagnostic purposes and
after surgery for postoperative monitoring and, where available,
residual blood was collected for the study. Residual blood sam-
ples also were taken immediately before euthanasia in Beagle
control dogs. The serum was separated and stored at 80°C.
A Quantikine Canine ELISA Kitj was used to measure the
serum concentration of VEGF.10–12
Samples from CPSS dogs before and after surgical attenuation
and control samples were analyzed in duplicate using an ELx808
absorbance microplate reader.k Sample concentration was calcu-
lated from the standard curve using Gen5 V1.07.5 software.k
Statistical Analysis
Analysis was performed using PASW Statistics 18.0.0 statisti-
cal software package.l Continuous data were visually assessed for
normality. Median and range were reported for skewed data,
which was compared with the Mann–Whitney U-test and Wilco-
xon paired ranks test as appropriate. Repeated measures were
compared with the Friedman’s two-way analysis of variance by
ranks with pair-wise comparison. The gene expression data was
transformed to normal distribution (square root or log). The data
then was compared with an independent t-test or paired sample
t-test. For all tests significance was set at the 5% level (P ≤ .05).
For each gene, the following comparisons were made: CPSS com-
pared to control; partial attenuation compared to complete atten-
uation; before and after partial attenuation (paired samples);
good portal blood flow (portovenogram grade 3 or 4) compared
to poor portal blood flow (portovenogram grade 1 or 2).
Results
qPCR Gene Expression
Clinical Findings. Liver samples from 49 dogs with
CPSS were included. The following breeds were repre-
sented in the study population: Yorkshire Terrier (7),
Crossbreed (6), Labrador (5), Miniature Schnauzer (5),
West Highland White Terrier (5), Cocker Spaniel (4),
Jack Russell Terrier (3), Bichon Frise (2), Golden
Retriever (2), Lhasa Apso (2), Pug (2), Chihuahua (1),
Hovawart (1), Irish Setter (1), Norfolk Terrier (1), Old
English Sheepdog (1), and Staffordshire Bull Terrier
(1). The median age was 275 days (range, 97–4,374).
Thirty-eight (77.6%) dogs had an extrahepatic CPSS
and 11 (22.4%) had an intrahepatic CPSS. Twenty-
four dogs (49%) had complete attenuation and 25
dogs (51%) had partial attenuation. All partial attenu-
ation dogs had repeat surgery a median of 110 days
(range, 69–358) postoperatively. Histopathologically
unremarkable liver tissue from 7 Beagle controls was
included. The median age of control dogs was
628 days (range, 515–1,544), and was significantly
greater than CPSS dogs (P = .036).
Portovenogram Grading. Complete portovenograms
were available for 47 dogs at first surgery and 21 dogs
at second surgery. Portovenogram grading results for
dogs at first and second surgery were consistent with a
previous study.1 Both pre- and postattenuation porto-
venogram grades at first surgery were significantly
greater for complete attenuation dogs compared with
partial attenuation dogs (both P < .001; Fig 1). For
dogs treated with partial attenuation, there was a sig-
nificant increase in portovenogram grade for both pre-
(P < .001) and post- (P = .001) complete temporary
CPSS attenuation from first to second surgery
(Table 2).
Gene Expression. Relative VEGFR2 mRNA expres-
sion was significantly greater in complete attenuation
dogs at a median of 12.885 (range, 2.459–22.454)
compared with partial attenuation dogs at a median of
9.140 (range, 3.724–19.556; P = .006). Relative
VEGFR2 mRNA expression significantly increased
after partial attenuation from a median of 9.140
(range, 3.724–19.556) to 10.493 (range, 4.814–17.409;
P = .037). There were no associations evident for
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Fig 1. Number of dogs tolerating partial or complete congenital portosystemic shunts (CPSS) attenuation at first surgery by pre- and
postattenuation portovenogram grade. There was a significant difference in portovenogram grade between the 2 groups (both P < .001).
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relative VEGF mRNA expression. All results are pre-
sented in Table 3 and statistically significant results are
presented graphically in Figure 2.
Relative VEGFR2 mRNA expression was signifi-
cantly greater in dogs with good portal blood flow
(portovenogram grade 3 or 4) at a median of 13.072
(range, 9.700–19.787) compared to those with poor
portal blood flow (portovenogram grade 1 or 2) at a
median of 9.246 (range, 2.459–22.454) on preattenua-
tion portovenograms (P = .001; Fig 3). There were no
additional associations between the relative mRNA
expression of VEGF or VEGFR2 and portovenogram
grade.
Serum VEGF Concentration
Clinical Findings. Serial serum samples taken before
surgery and at 24, 48, and 72 hours postsurgery from
35 dogs with CPSS were included. The following
breeds were represented in the study population: Mini-
ature Schnauzer (5), Crossbreed (4), Yorkshire Terrier
(4), Cocker Spaniel (3), Labrador (3), West Highland
White Terrier (3), Jack Russell Terrier (2), Pug (2),
Bichon Frise (1), Border Collie (1), Border Terrier (1),
Lhasa Apso (1), Norfolk Terrier (1), Shih Tzu (1),
Springer Spaniel (1), Staffordshire Bull Terrier (1), and
Tibetan Terrier (1). The median age of CPSS dogs was
385 days (range, 107–4,374). Twenty-nine (82.9%)
dogs had an extrahepatic CPSS and six (17.1%) had
an intrahepatic CPSS. Sixteen dogs (45.7%) had com-
plete attenuation and 19 (54.3%) had partial attenua-
tion. Serum samples from 5 healthy Beagle dogs and 6
dogs undergoing abdominal surgery were included as
controls. The six dogs undergoing abdominal surgery
also had a 24-hour postsurgery sample taken. The fol-
lowing breeds were represented in the control popula-
tion: Beagle (5), Crossbreed (2), Cocker Spaniel (1),
German Shepherd Dog (1), Labrador (1) and Shar Pei
(1). The median age of control dogs was 1,544 days
(range, 526–3,971), which was significantly greater than
the age of CPSS dogs (P = .002).
Serum VEGF Concentration. The median preopera-
tive VEGF concentration for CPSS dogs was 37.8 pg/
mL (range, 5.7–85.3) and for control dogs was 64.3 pg/
mL (range, 1.9–178.4). This difference was not signifi-
cant. The median VEGF concentration at 24 hours in
CPSS dogs was 66.4 pg/mL (range, 9.6–156.2), at
48 hours was 50.3 pg/mL (range, 16.4–221.1) and at
72 hours was 40.5 pg/mL (range, 9.0–121.7; Fig 4).
There was a significant difference in the concentration
of VEGF at the different time points (P < .001). Pair-
wise comparison of this data set confirmed that VEGF
concentration at 24 hours (P < .001) and 48 hours
(P = .003) postsurgery were significantly greater than
concentrations presurgery.
For the 6 control dogs with pre- and postsurgical
samples, the median VEGF concentration presurgery
was 83.8 pg/mL (range, 23.4–178.4) and at 24 hours
postoperatively was 76.4 pg/mL (range, 11.8–132.1).
This difference was not statistically significant.
The intra-assay variability was low with a
median coefficient of variation (CV) of 4.1 (range,
0.0–40.9).
Discussion
The aim of this study was to investigate whether
markers of angiogenesis are associated with the degree
of liver and portal vasculature development and the
hepatic vascular response to attenuation in dogs with
CPSS. We found that VEGFR2 mRNA expression
increased significantly after partial CPSS attenuation.
We also found that VEGFR2 mRNA expression was
greater in dogs with a more developed portal blood
supply at the time of first surgery. These findings are
consistent with an increased binding capacity for
VEGF, suggesting that angiogenesis is occurring and
therefore contributing, at least in part, to the increased
vascularization in dogs with CPSS. This concept is
supported by the fact that there also was a significant
increase in portal blood flow after partial attenuation.
In addition, we found that serum VEGF concentra-
tions were significantly increased 24 and 48 hours
postsurgery. These findings support the concept that
angiogenesis occurs after CPSS attenuation and is
involved in the improvement in portal vasculature.
Vascular endothelial growth factor receptor 2 is the
major receptor mediating the angiogenic actions of
VEGF and its expression is increased during angiogen-
esis and down-regulated in quiescent tissue.3,13,14
VEGF produced by hepatocytes acts in a paracrine
manner, interacting with its receptors on endothelial
cells to regulate endothelial cell growth and liver vas-
cularization after experimental partial hepatectomy
Table 2. Portovenogram grade before and after temporary CPSS attenuation in 21 dogs at first and second
surgery.
Timing of Assessment
Number (%) of Dogs for Each Portovenogram Grade
Grade 1 Grade 2 Grade 3 Grade 4
1st Surgery preattenuation 18 (85.7) 3 (14.3) 0 (0) 0 (0)
1st Surgery postattenuation 0 (0) 12 (57.1) 9 (42.9) 0 (0)
2nd Surgery preattenuation 2 (9.5) 8 (38.1) 6 (28.6) 5 (23.8)
2nd Surgery postattenuation 0 (0) 4 (19.0) 6 (28.6) 11 (52.4)
There was a statistically significant increase in portovenogram grade for both pre- and postattenuation from first to second surgery
(P < .001 and P = .001).
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(PH).15,16 Hepatocyte expression of VEGF and endo-
thelial expression of VEGFR2 both increase after PH
in the rat, peaking at 48–72 hours and associated with
the proliferation of endothelial cells.16–20 PH is a
model of liver regeneration and in addition the
increased mass requires the synthesis of new blood ves-
sels.21 Previous work has identified associations
between markers of hepatocyte proliferation and surgi-
cal attenuation of CPSS.22 These data support the
hypothesis that liver regeneration occurs after CPSS
attenuation and this increased liver volume would
intuitively require an increased blood supply.
If angiogenesis occurred after partial CPSS attenua-
tion then similar increases in VEGF and VEGFR2
mRNA expression might be expected. We previously
used immunohistochemistry to measure endothelial cell
expression of VEGF and VEGFR2 in liver tissue from
dogs with CPSS.6 This study found that endothelial
VEGF was up-regulated and endothelial VEGFR2 was
down-regulated in CPSS dogs and that there was a
decrease in endothelial VEGF and an increase in endo-
thelial VEGFR2 after partial CPSS attenuation. These
findings suggested that angiogenesis is involved in the
vascular response to CPSS attenuation.
This study used qPCR to measure the relative
mRNA expression of VEGF and VEGFR2 in liver tis-
sue from dogs with CPSS. VEGFR2 mRNA expres-
sion significantly increased after partial CPSS
attenuation. Thus, VEGFR2 mRNA expression
increases after partial attenuation, presumably related
to increased portal blood flow. This is supported by
the results of the portovenogram analysis, which
showed significant increases in portovenogram grade,
and hence increases in portal flow, from first to second
surgery.
Thus, an increase in VEGFR2 mRNA expression
is associated with development of the vasculature.
VEGFR2 mRNA expression also was significantly
greater in dogs that could tolerate a complete attenu-
ation compared to those that tolerated partial atten-
uation. Dogs that tolerated complete attenuation also
had significantly greater intrahepatic portal blood
flow based on portovenogram grade. These findings
are supported by the fact that expression of VEG-
FR2 mRNA was significantly greater for dogs with
well-developed portal blood flow (portovenogram
grades 3 and 4) compared to those with poor flow
(portovenogram grades 1 and 2). Thus, VEGFR2
mRNA expression is associated with a more devel-
oped liver and more developed intrahepatic vascula-
ture, suggesting a possible role for angiogenesis in
vascular development in CPSS dogs. VEGFR2
mRNA expression represents VEGF binding capacity
and hence may be a better marker of vascular devel-
opment than VEGF itself. These findings support the
hypothesis that angiogenesis is involved in the hepa-
tic response to surgical CPSS attenuation. Thus, it
can be inferred that improvement in intrahepatic
portal vasculature is, at least in part, because of
angiogenesis. This finding has important implications
for development of novel treatment strategies forT
a
b
le
3
.
R
el
a
ti
v
e
m
R
N
A
ex
p
re
ss
io
n
o
f
V
E
G
F
a
n
d
it
s
re
ce
p
to
r
V
E
G
F
R
2
in
li
v
er
b
io
p
si
es
fr
o
m
d
o
g
s
w
it
h
C
P
S
S
a
n
d
co
n
tr
o
l
d
o
g
s.
F
o
r
ea
ch
g
en
e
th
e
fo
ll
o
w
in
g
co
m
p
a
ri
so
n
s
w
er
e
m
a
d
e:
C
P
S
S
co
m
p
a
re
d
to
co
n
tr
o
l;
p
a
rt
ia
l
a
tt
en
u
a
ti
o
n
co
m
p
a
re
d
to
co
m
p
le
te
a
tt
en
u
a
ti
o
n
;
b
ef
o
re
a
n
d
a
ft
er
p
a
rt
ia
l
a
tt
en
u
a
ti
o
n
(p
a
ir
ed
sa
m
p
le
s)
.
G
en
e
C
o
n
tr
o
l
C
o
m
p
a
re
d
to
C
P
S
S
C
o
m
p
le
te
A
tt
en
u
a
ti
o
n
C
o
m
p
a
re
d
to
P
a
rt
ia
l
A
tt
en
u
a
ti
o
n
B
ef
o
re
a
n
d
A
ft
er
P
a
rt
ia
l
A
tt
en
u
a
ti
o
n
C
o
n
tr
o
l
C
P
S
S
P
-V
a
lu
e
P
a
rt
ia
l
C
o
m
p
le
te
P
-V
a
lu
e
B
ef
o
re
P
a
rt
ia
l
A
tt
en
u
a
ti
o
n
A
ft
er
P
a
rt
ia
l
A
tt
en
u
a
ti
o
n
P
-V
a
lu
e
V
E
G
F
9
.8
7
5
(7
.0
7
4
–1
1
.7
7
5
)
1
0
.2
2
0
(2
.2
4
2
–1
9
.5
3
8
)
.3
9
6
8
.7
9
4
(5
.9
5
9
–1
8
.0
3
3
)
1
1
.0
9
8
(2
.2
4
2
–1
9
.5
3
8
)
.0
8
1
8
.7
9
4
(5
.9
5
9
–1
8
.0
3
3
)
1
0
.4
5
9
(6
.3
5
4
–1
7
.1
1
8
)
.1
5
3
V
E
G
F
R
2
7
.6
8
4
(5
.7
8
3
–1
5
.7
6
7
)
1
0
.9
1
6
(2
.4
5
9
–2
2
.4
5
4
)
.4
0
6
9
.1
4
0
(3
.7
2
4
–1
9
.5
5
6
)
1
2
.8
8
5
(2
.4
5
9
–2
2
.4
5
4
)
.0
0
6
9
.1
4
0
(3
.7
2
4
–1
9
.5
5
6
)
1
0
.4
9
3
(4
.8
1
4
–1
7
.4
0
9
)
.0
3
7
V
E
G
F
,
v
a
sc
u
la
r
en
d
o
th
el
ia
l
g
ro
w
th
fa
ct
o
r;
V
E
G
F
R
2
,
V
E
G
F
re
ce
p
to
r
2
;
C
P
S
S
,
co
n
g
en
it
a
l
p
o
rt
o
sy
st
em
ic
sh
u
n
ts
R
es
u
lt
s
a
re
g
iv
en
a
s
m
ed
ia
n
a
n
d
ra
n
g
e.
S
ta
ti
st
ic
a
l
si
g
n
ifi
ca
n
ce
w
a
s
se
t
a
t
th
e
5
%
le
v
el
(P
≤
.0
5
).
S
ig
n
ifi
ca
n
t
P
-v
a
lu
es
a
re
h
ig
h
li
g
h
te
d
in
b
o
ld
a
n
d
it
a
li
cs
.
1428 Tivers et al
dogs with CPSS. A previous study investigated the
administration of recombinant HGF to promote
hepatic regeneration in dogs with CPSS.23 Liver vol-
ume increased in response to recombinant HGF,
demonstrating that this approach has potential but
the increase was not sustained after withdrawal of
treatment. Serum VEGF concentration potentially
could be used to assess the response to CPSS attenu-
ation in the postoperative period, although probably
in concert with imaging of the intrahepatic vascula-
ture.
The results of this study agree with previous data
demonstrating that VEGFR2 is a marker of angiogen-
esis in CPSS dogs.6 In the previous study, endothelial
VEGFR2 increased after partial attenuation, similar to
the increase in VEGFR2 mRNA expression seen in
this study. However, the previous study also identified
that endothelial VEGF was up-regulated in CPSS dogs
compared with controls and decreased after partial
attenuation. Similar changes in VEGF mRNA expres-
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Fig 2. Relative vascular endothelial growth factor receptor 2 (VEGFR2) mRNA expression in liver biopsy samples from dogs with con-
genital portosystemic shunts (CPSS). The graphs show significant findings for VEGFR2. Statistical significance is highlighted with the
appropriate P value.
Fig 3. Relative mRNA expression of vascular endothelial
growth factor receptor 2 (VEGFR2) in liver biopsy samples from
dogs with congenital portosystemic shunts (CPSS) as related to
portal blood flow on preattenuation portovenogram. Portoveno-
gram grades of 1 and 2 were considered poor portal blood flow
and portovenogram grades of 3 and 4 were considered good por-
tal blood flow. There was a significant difference between the
groups (P = .001).
Fig 4. Serum vascular endothelial growth factor (VEGF) con-
centration in congenital portosystemic shunts (CPSS) dogs pres-
urgery and 24, 48, and 72 hours postsurgery. VEGF
concentration was measured using a canine VEGF ELISA kit.
There was a significant difference in the concentration of VEGF
at the different time points (P < .001). Pair-wise comparison of
this data set confirmed that VEGF 24 hours (P < .001) and
48 hours (P = .003) postsurgery were significantly greater than
presurgery.
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sion were not identified in this study. This discrepancy
may be related to the different methodologies used to
measure VEGF. This study used qPCR to measure
mRNA expression and it is important to note that this
does not necessarily translate directly into protein
expression. In addition, the previous study specifically
assessed endothelial VEGF protein whereas this study
measured VEGF mRNA expression in liver tissue as a
whole. This study also used a different and smaller
group of dogs and this also could have influenced the
results.
Based on the nature of the clinical cases in this
study, there were limitations on what tissue was avail-
able for analysis. It would have been interesting to
compare hepatic biopsy samples at first surgery with
samples taken in the immediate postoperative period
because more acute changes in VEGF and VEGFR2
mRNA expression may have been detectable. How-
ever, hepatic tissue was only available at first surgery
from all dogs and then at follow-up surgery in dogs
treated with partial attenuation. Thus, we were only
able to detect changes in hepatic gene expression at
these time points. Nevertheless, this study provides
novel information regarding the activity of these mark-
ers in dogs with CPSS.
To gain insight into the immediate perioperative
period, serum VEGF concentrations before and after
surgery also were measured. Serum VEGF concentra-
tion was significantly increased at 24 and 48 hours
after CPSS attenuation compared with presur-
gery. Several studies of PH in rats have shown
increased expression of VEGF and VEGFR2 in
hepatic tissue postoperatively, confirming a role in
liver regeneration.17–20,24 These changes were maximal
at 48–72 hours and decreased thereafter.17,18,20 The
increases in VEGF and VEGFR2 were associated
with endothelial cell proliferation, indicating
angiogenesis.17,20 This increase in VEGF expression
in hepatic tissue could result in increased protein
production and increased VEGF in the peripheral
blood. In 1 study, VEGF was detectable in periph-
eral blood 72 hours after PH in rats but not
before.18 In a clinical study of people undergoing PH
for liver donation, significant increases in VEGF
compared with presurgery concentrations were seen
at days 4 and 5 postoperatively.25 The increase in
VEGF after CPSS attenuation would indicate
increased production of VEGF associated with
increased hepatic portal blood flow and liver regener-
ation, similar to the increases seen in the studies
described above. VEGF plays an important role in
wound healing, and studies have shown increased
VEGF concentration in both serum and wound fluid
after surgery.26–28 The increases in serum VEGF seen
in the current study may have been as a result of
wound healing rather than related to changes in
hepatic vasculature. However, in the experimental
and clinical studies of PH the increases in serum
VEGF were attributed to hepatic angiogenesis rather
than wound healing. Studies investigating wound
healing after surgery typically have shown maximal
increases in VEGF concentration 7–14 days postoper-
atively with concentrations also remaining increased
after this time.26–28 This is contrary to the more
acute and short-lived increase seen in studies of PH
and after CPSS attenuation in the current study.
A control group of breed- and age-matched dogs
undergoing abdominal surgery for reasons other than
CPSS or liver resection would have provided addi-
tional information on the specificity of VEGF as a
marker of angiogenesis. Indeed, a cohort of dogs
undergoing PH would have provided useful informa-
tion for comparison. Unfortunately, such controls were
not available. A small number of dogs undergoing
abdominal surgery with pre- and postoperative sam-
ples were tested for VEGF and did not show a signifi-
cant increase after surgery, although this may have
been because of type II statistical error. In addition,
there was a wide range of VEGF concentrations seen
in the control dogs and this may have influenced the
results. A much larger control group would have been
ideal and potentially would have allowed stronger con-
clusions to be drawn. Control dogs also were
significantly older than the CPSS dogs and this may
have influenced the results. Studies have shown that
serum VEGF concentrations are significantly higher in
fetuses and neonates compared to adults but that there
is no significant difference in serum VEGF between
children and adults or among children of different
ages.29,30 The main focus of this part of the study was
to investigate changes in VEGF concentration in CPSS
dogs before and after surgery, and this was
independent of the starting concentration. Our findings
provide good evidence that angiogenesis occurs in
CPSS dogs in response to increased blood flow caused
by CPSS attenuation.
This part of the study included a 72-hour
postsurgery sample for assessment of VEGF concen-
tration because previous studies in rats and people
had suggested that VEGF concentrations would be
maximal at this time point. In the CPSS dogs,
VEGF was detectable at all time points and the
concentrations at 72 hours were not significantly dif-
ferent from presurgery concentrations. Many vari-
ables may have contributed to this difference
although the difference in species and the trigger for
angiogenesis are likely to have played a major role.
Because of the ethical issues discussed above, it was
not possible to take blood purely for this study.
Residual blood was collected when samples were
taken for routine diagnostic purposes, which dictated
the amount of blood available and the time at which
it was collected. Blood samples taken earlier than
24 hours postoperatively may have demonstrated
even greater increases in VEGF. A commercial
ELISA kit was used for the measurement of serum
VEGF because it was canine specific and had been
used in previously published studies, demonstrating
that it was able to detect the corresponding antigen
in canine samples.10–12
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